Abstract
Diffuse gliomas are tumors that arise from glial or glial progenitor cells that have historically been classified as low-grade glioma (LGG), a slower-growing tumor, and glioblastoma (GBM), a more aggressive tumor. Despite advances in the diagnosis and treatment of glioma, the median survival time after diagnosis of GBM remains low, approximately 15 months, and with a 5-year overall survival rate of only 6.8%. Therefore, new biomarkers that could support earlier diagnosis and prognosis of these tumors would be of great value. MUC17, a member of the membrane-bound mucins, has been identified as a potential biomarker in several tumors. However, this mucin is unexplored in adult gliomas. Here we have shown for the first time in a retrospective study and by in silico analysis that MUC17 is one of the relevant mutant genes in adult gliomas and that the increase in MUC17 methylation correlates with the increase in glioma grade malignancy. Patients with MUC17 mutation had a poorer prognosis compared to their wild-type counterparts in both the LGG and GBM cohorts. We also analyzed which mutational profile correlates more strongly with poor survival. Therefore, in the present work, we present a new potential biomarker to be investigated for the diagnosis and prognosis in adult diffuse glioma.
Key points MUC17 accounts the mutational burden in gliomas
Mutated MUC17 is associated with poor prognosis in both LGG and GBM cohorts
MUC17 methylation rate increases with tumor grade in gliomas
The C > T base change is the most common missense MUC17 mutation in GBM and correlates with a poorer prognosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors